Results 41 to 50 of about 4,616 (237)

Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study

Scientific Reports, 2023
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory osteonecrosis caused by antiresorptive agents such as bisphosphonate and denosumab (DMB).
Yuki Sakamoto, Shunsuke Sawada, Yuka Kojima   +2 more
doaj   +1 more source

Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ)

Oral Diseases
This paper aims to describe the 2023 update position paper on MRONJ developed by the Italian Societies of Oral Pathology and Medicine (SIPMO) and of Maxillofacial Surgery (SICMF).
A. Bedogni, R. Mauceri, V. Fusco, F. Bertoldo, G. Bettini, O. Di Fede, Antonio Lo Casto, Claudio Marchetti, V. Panzarella, G. Saia, P. Vescovi, G. Campisi   +11 more
semanticscholar   +1 more source

Risk factors for the development of medication-related osteonecrosis of the jaw and effects of tooth extraction with local infection

Journal of Dental Sciences
Background/purpose: Tooth extraction has been avoided in patients receiving antiresorptive agent (ARA) therapy. This study aimed to investigate dental findings associated with medication-related osteonecrosis of the jaw (MRONJ) development in patients ...
Norio Nakamura, Mitsunobu Otsuru, Taro Miyoshi, Koki Suyama, Keisuke Omori, Kota Morishita, Sakiko Soutome, Satoshi Rokutanda, Kei-ichiro Miura, Masahiro Umeda   +9 more
doaj   +1 more source

Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis – A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso)

Archives of Endocrinology and Metabolism, 2020
Antiresorptive therapy is the main form of prevention of osteoporotic or fragility fractures. Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but severe adverse reaction to antiresorptive and antiangiogenic drugs.
Miguel Madeira, André Caroli Rocha, Carolina Aguiar Moreira, Águida Maria Menezes Aguiar, Sergio Setsuo Maeda, Abel Silveira Cardoso, Charlles Heldan de Moura Castro, Catarina Brasil D'Alva, Barbara Campolina Carvalho Silva, Bruno Ferraz-de-Souza, Marise Lazaretti-Castro, Francisco Bandeira, Sandra R. Torres   +12 more
doaj   +1 more source

Advancements in Bone Replacement Techniques–Potential Uses After Maxillary and Mandibular Resections Due to Medication-Related Osteonecrosis of the Jaw (MRONJ)

Cells
Maxillofacial bone defects can have a profound impact on both facial function and aesthetics. While various biomaterial scaffolds have shown promise in addressing these challenges, regenerating bone in this region remains complex due to its irregular ...
J. Bóvári-Biri, Judith A Miskei, Zsanett Kover, Alexandra Steinerbrunner-Nagy, Kinga Kardos, P. Maróti, J. Pongrácz   +6 more
semanticscholar   +1 more source

The Therapeutic Effectiveness Using Fluorescence‐Guided Surgery for MRONJ

BioMed Research International, 2022
Background. Long‐term application of antiresorptive and/or antiangiogenic agents may cause oral disorders, including medication‐related osteonecrosis of the jaw (MRONJ), which remains an incurable disease. Surgical treatment can help alleviate infection of the jaw and block the progress of the disease, but postoperative recurrence is often caused by ...
Hongyuan Huang, Ning Zhao, Qingxiang Li, Qiao Qiao, Jianya Zhang, Chuanbin Guo, Yuxing Guo   +6 more
openaire   +2 more sources

Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol

Journal of Clinical Medicine
Background: This study aimed to evaluate the efficacy of pentoxifylline and tocopherol therapy in patients with medication-related osteonecrosis of the jaw (MRONJ).
Łukasz Słowik, Ewa Totoń, A. Nowak, Aleksandra Wysocka-Słowik, M. Okła, Z. Ślebioda   +5 more
semanticscholar   +1 more source

Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone‐Related Diseases

Cell Proliferation, EarlyView.
Engineered BMSCs and vesicles enhance therapy effects for bone diseases via multi‐strategic approaches. ABSTRACT Bone‐related diseases (e.g., osteoporosis, osteoarthritis and fractures) exhibit a rising global incidence, imposing significant burdens on both quality of life and healthcare systems.
Xuemei Long, Dan Tan, Qianke Tao, Qiaonan Ye, Luwen Ye, Qing Li, Jingang Xiao   +6 more
wiley   +1 more source

Chronic Periodontal Infection and Not Iatrogenic Interference Is the Trigger of Medication-Related Osteonecrosis of the Jaw: Insights from a Large Animal Study (PerioBRONJ Pig Model)

Medicina, 2023
Background and Objectives: Antiresorptive drugs are widely used in osteology and oncology. An important adverse effect of these drugs is medication-induced osteonecrosis of the jaw (MRONJ).
Matthias Troeltzsch, Stephan Zeiter, Daniel Arens, Dirk Nehrbass, Florian A. Probst, Paris Liokatis, Michael Ehrenfeld, Sven Otto   +7 more
doaj   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source